This comprehensive laboratory guide evaluates the structural chemistry, receptor dynamics, and pharmacokinetic profile of the CJC-1295 Drug Affinity Complex (DAC). Designed strictly for institutional researchers and laboratory procurement specialists, this resource outlines the empirical mechanisms, analytical testing benchmarks, and comparative characteristics of long-acting growth hormone-releasing hormone analogs.
This comprehensive laboratory guide evaluates the structural chemistry, receptor dynamics, and pharmacokinetic profile of the CJC-1295 Drug Affinity Complex (DAC). Designed strictly for institutional researchers and laboratory procurement specialists, this resource outlines the empirical mechanisms, analytical testing benchmarks, and comparative characteristics of long-acting growth hormone-releasing hormone analogs.
The CJC-1295 Drug Affinity Complex (CJC-1295 DAC) is a synthetic 30-amino acid growth hormone-releasing hormone (GHRH) analog featuring a bi-functional maleimido-propionic acid linker. This modification enables covalent binding to endogenous serum albumin post-administration in animal models, extending the compound's terminal half-life from minutes to approximately 6 to 8 days, sustaining steady-state growth hormone (GH) and IGF-1 elevation for tissue repair research.
Unlike short-acting native GHRH(1-29) peptides that experience rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), the incorporation of the Drug Affinity Complex (DAC) technology shields the peptide core. For institutional investigators utilizing our growth hormone secretagogue mechanisms library, CJC-1295 DAC represents a foundational tool for studying persistent endocrine signal transduction without requiring frequent pulsatile dosing protocols.
At a molecular level, CJC-1295 with DAC is engineered by modifying the native GHRH sequence at specific residue positions to enhance chemical stability. Substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu) protect the N-terminal sequence against cleavage, while the Lys30 residue is conjugated to a maleimidopropionic acid (MPA) linker. This specific reactive linker targets the free cysteine-34 thiol group on circulating albumin.
Preclinical in vitro assays demonstrate that upon exposure to biological fluids containing albumin, the MPA linker forms a stable, irreversible thioether bond. Because serum albumin has a long circulatory half-life, the conjugated peptide acts as a dynamic reservoir. Researchers analyzing high-purity analytical standards note that this unique conjugation mechanism prevents renal filtration and enzymatic neutralization, making the complex ideal for longitudinal cell culture and animal tissue regeneration research.
As a potent GHRH analog, CJC-1295 DAC targets the GHRH receptors (GHRHR) located on anterior pituitary somatotropes. Receptor activation stimulates the intracellular cAMP/protein kinase A (PKA) signaling pathway, resulting in transcription and exocytosis of growth hormone. Because of the sustained systemic presence provided by the Drug Affinity Complex, somatotrophic stimulation occurs continuously rather than in isolated transient spikes.
In preclinical animal models, continuous GHRH receptor stimulation elevates baseline serum GH levels, which in turn stimulates hepatic production of insulin-like growth factor 1 (IGF-1). Published data indicate that IGF-1 acts as a primary mediator of cellular proliferation, satellite cell activation in skeletal muscle, extracellular matrix synthesis, and localized tissue repair. Researchers exploring tissue regeneration protocols utilize CJC-1295 DAC to measure long-term transcriptomic changes in collagen synthesis and osteoblast differentiation.
When procurement departments evaluate the query "cjc price 1295" across commercial reagent vendors, significant variances in baseline valuation emerge. These cost disparities are rarely driven by raw peptide sequence synthesis alone; rather, they reflect critical differences in purification methodology, linker coupling efficiency, and third-party analytical verification.
The synthesis of a peptide featuring a reactive maleimide linker requires specialized purification protocols to prevent premature polymerization or hydrolytic degradation of the DAC moiety. Low-cost formulations often omit multi-pass Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) or fail to conduct comprehensive mass spectrometry (MS). Procurement teams must evaluate cost-per-milligram against verified purity, ensuring that every batch contains active, unhydrolyzed maleimide functionality required for quantitative experiment replication.
Inquiries surrounding "cjc-1295 dac pharmacy" context often stem from comparative literature examining human clinical trials versus academic laboratory reagents. Historically, clinical-grade formulations synthesized under human compounding regulations targeted human clinical trials. However, laboratory investigators must distinguish between clinical compounding standards and specialized analytical research materials.
For non-human laboratory experimentation, purchasing high-purity research reagents from a specialized USA supplier ensures strict compliance with ISO 17025 testing standards. While a pharmacy formulation is intended for sterile clinical administration, PX1 Research provides CJC-1295 DAC synthesized specifically for in vitro assays, microfluidic cell culture, and animal models, accompanied by complete lot-specific certificates of analysis (COAs) detailing chemical identity and absolute purity.
To properly contextualize CJC-1295 DAC within a secretagogue screening study, researchers must compare its performance metrics against non-conjugated analogs and ghrelin receptor agonists. The primary distinction between CJC-1295 DAC and modified GRF(1-29) lies entirely in the terminal half-life and secretion kinetics. While modified GRF(1-29) generates a rapid, transient GH spike lasting approximately 30 minutes, the DAC variant maintains elevated baseline secretion over several days.
When designing multi-arm secretagogue protocols, investigators frequently compare CJC-1295 DAC to CJC-1295 without DAC, Sermorelin, Tesamorelin, and ghrelin mimetics such as Ipamorelin. Whereas Tesamorelin is optimized for high-specificity GHRH receptor binding with native-like pulsatility, CJC-1295 DAC is selected specifically when continuous baseline exposure is required. Combining GHRH analogs with ghrelin receptor agonists in preclinical models often reveals synergistic GH output, offering a dual mechanism for studying somatotrope desensitization.
To ensure reproducible experimental outcomes, institutional laboratories must apply rigorous quality criteria when sourcing CJC-1295 DAC. Substandard peptide reagents with unverified impurities introduce confounding variables into receptor binding studies and cell viability assays. The following criteria represent the gold standard for laboratory procurement:
• Third-Party COA per Lot: Complete transparency with independent laboratory verification for every individual production lot. • HPLC & Mass Spectrometry: Analytical RP-HPLC confirming ≥98% chemical purity alongside Electrospray Ionization Mass Spectrometry (ESI-MS) confirming precise molecular weight. • Endotoxin Testing: Quantitative Chromogenic LAL assays ensuring bacterial endotoxin levels remain below 0.01 EU/mg for sensitive cell cultures. • US Manufacturing & Traceability: Domestic synthesis within GMP-compliant, ISO 17025 accredited facilities to guarantee supply chain integrity. • Rapid Logistics: Same-day shipping from dual fulfillment centers (California and Arizona) to minimize thermal degradation during transit.
Proper handling of lyophilized CJC-1295 DAC is essential to maintain the reactivity of the maleimidopropionic acid linker. Upon receipt, lyophilized vials should be stored in a desiccant-equipped freezer at -20°C or -80°C to prevent moisture absorption and hydrolysis of the functional groups.
For reconstitution in laboratory settings, sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline should be introduced along the internal glass wall of the vial to minimize agitation. Avoid violent vortexing, as shear forces can denature delicate peptide chains. Once reconstituted, stock solutions must be aliquoted into single-use microcentrifuge tubes to eliminate freeze-thaw cycles and maintained at 2°C to 8°C for short-term assay procedures. For researchers managing high-throughput screening, establishing standard operating procedures via bulk lab accounts ensures consistent batch access.
Global academic collaborations frequently search terms such as "cjc-1295 dac prijs" when comparing European and North American supplier standards. The Dutch and European research communities prioritize precise chemical specifications, regulatory compliance, and international shipping integrity when procuring US-manufactured peptides.
Evaluating international price-to-quality metrics requires looking beyond the sticker cost per vial. Factors such as international cold-chain packaging, import compliance verification, and validated endotoxin limits dictate the true value of research compounds. PX1 Research supports international research initiatives by providing fully documented, high-purity reagents that eliminate experimental failures caused by low-grade imported raw materials.
What is "cjc-1295" "drug affinity complex" in peptide research?
The CJC-1295 Drug Affinity Complex is a modified 30-amino acid GHRH analog containing a maleimido-propionic acid linker. This linker allows the peptide to covalently bind to endogenous serum albumin in preclinical models, significantly extending its half-life to 6–8 days for long-term somatotrope research.
How does the Drug Affinity Complex (DAC) alter CJC-1295 half-life?
Without DAC, short-acting GHRH analogs are rapidly cleared by DPP-IV enzymes within 30 minutes. The DAC modification selectively targets the cysteine-34 residue of albumin, creating a stable complex that protects the peptide from enzymatic degradation and renal filtration.
How should laboratories evaluate "cjc price 1295" across vendors?
Laboratories evaluating "cjc price 1295" should look beyond base cost and assess raw HPLC purity metrics (≥98%), lot-specific mass spectrometry validation, endotoxin testing (<0.01 EU/mg), and maleimide linker integrity to ensure experimental reproducibility.
What differentiates "cjc-1295 dac pharmacy" grade from research-grade compounds?
While "cjc-1295 dac pharmacy" inquiries refer to historical compounding for clinical studies, research-grade CJC-1295 DAC from PX1 Research is manufactured specifically for non-human in vitro and animal models, featuring ISO 17025 analytical verification and full COA lot traceability.
What factors account for international search queries like "cjc-1295 dac prijs"?
The phrase "cjc-1295 dac prijs" reflects European research procurement queries comparing global supplier pricing against stringent chemical purity standards, cold-chain delivery reliability, and analytical documentation.
What receptor pathways are targeted by CJC-1295 DAC?
CJC-1295 DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotropes, stimulating intracellular cAMP/PKA pathways to elevate GH and downstream hepatic IGF-1 output.
How does CJC-1295 DAC differ from CJC-1295 without DAC?
CJC-1295 DAC includes a reactive maleimide linker that extends its biological half-life to several days, creating continuous GH elevation. CJC-1295 without DAC lacks this linker, resulting in a short half-life that mimics natural pulsatile GH release.
What reconstitution diluent is recommended for laboratory CJC-1295 DAC assays?
CJC-1295 DAC is typically reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS), depending on the specific requirements of the downstream in vitro or in vivo model.
Why is endotoxin testing critical for CJC-1295 DAC research batches?
Bacterial endotoxins (LPS) cause inflammatory responses and microglial activation in cell culture and animal models, invalidating experimental data. PX1 Research verifies that all lots contain <0.01 EU/mg via Chromogenic LAL testing.
How should reconstituted CJC-1295 DAC stock solutions be stored in the lab?
Reconstituted CJC-1295 DAC should be divided into single-use aliquots and stored at 2°C to 8°C for short-term use (up to 14 days) or -80°C for extended storage, avoiding repeated freeze-thaw cycles.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.